Ceritinib

Metastatic Pancreatic Adenocarcinoma

Criterium, Inc.Small moleculePhase 2Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 81/ 100

Competitive context

190 Active assets in the Metastatic Pancreatic Adenocarcinoma cohort.

Asset / Sponsor	Phase	Rating
FLUOROURACILUM Jonsson Comprehensive Cancer Center	Phase 4	BBB
Docetaxel Bristol-Myers Squibb	Phase 2	BBB
Eloxatin Jonsson Comprehensive Cancer Center	Phase 4	BB
Irinotecan Jonsson Comprehensive Cancer Center	Phase 3	BB
Irinotecan Ipsen	Phase 3	BB

View all 50 →

Same molecule, other indications

Ceritinib is also rated in:

non-small cell lung carcinomaDormant

B

Indicative ·

60 / 100

Adenocarcinoma Lung Cancer; Squamous Cell Lung CarcinomaDormant

B

Indicative ·

56 / 100

ALK Fusion Protein ExpressionDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.